274 related articles for article (PubMed ID: 32416870)
1. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
2. Bitopic Binding Mode of an M
Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
[TBL] [Abstract][Full Text] [Related]
3. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
4. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
[TBL] [Abstract][Full Text] [Related]
5. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
[TBL] [Abstract][Full Text] [Related]
6. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
Davie BJ; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787
[TBL] [Abstract][Full Text] [Related]
7. Positive allosteric modulation of M
Yohn SE; Conn PJ
Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
Verma S; Kumar A; Tripathi T; Kumar A
J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
[TBL] [Abstract][Full Text] [Related]
9. SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs).
Kuduk SD; Beshore DC
Curr Top Med Chem; 2014; 14(15):1738-54. PubMed ID: 25176125
[TBL] [Abstract][Full Text] [Related]
10. M1 agonists as a potential disease-modifying therapy for Alzheimer's disease.
Caccamo A; Fisher A; LaFerla FM
Curr Alzheimer Res; 2009 Apr; 6(2):112-7. PubMed ID: 19355845
[TBL] [Abstract][Full Text] [Related]
11. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
12. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
Lazareno S; Popham A; Birdsall NJ
J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
[TBL] [Abstract][Full Text] [Related]
13. M1 muscarinic acetylcholine receptor in Alzheimer's disease.
Jiang S; Li Y; Zhang C; Zhao Y; Bu G; Xu H; Zhang YW
Neurosci Bull; 2014 Apr; 30(2):295-307. PubMed ID: 24590577
[TBL] [Abstract][Full Text] [Related]
14. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
Fisher A
Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
[TBL] [Abstract][Full Text] [Related]
15. A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice.
Abd-Elrahman KS; Sarasija S; Colson TL; Ferguson SSG
Br J Pharmacol; 2022 Apr; 179(8):1769-1783. PubMed ID: 34820835
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M
van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A
Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279
[TBL] [Abstract][Full Text] [Related]
17. Diverse Effects on M
Rook JM; Abe M; Cho HP; Nance KD; Luscombe VB; Adams JJ; Dickerson JW; Remke DH; Garcia-Barrantes PM; Engers DW; Engers JL; Chang S; Foster JJ; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Lindsley CW
ACS Chem Neurosci; 2017 Apr; 8(4):866-883. PubMed ID: 28001356
[TBL] [Abstract][Full Text] [Related]
18. Structural Features of Iperoxo-BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy.
Wakeham MCL; Davie BJ; Chalmers DK; Christopoulos A; Capuano B; Valant C; Scammells PJ
ACS Chem Neurosci; 2022 Jan; 13(1):97-111. PubMed ID: 34905693
[TBL] [Abstract][Full Text] [Related]
19. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.
Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM
Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561
[TBL] [Abstract][Full Text] [Related]
20. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
McArthur RA; Gray J; Schreiber R
Curr Opin Investig Drugs; 2010 Jul; 11(7):740-60. PubMed ID: 20571970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
